Marie Cullberg

Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial

Paul M. O’Byrne, Hristo Metev, Margareta Puu et al. · The Lancet Respiratory Medicine · 2016 · 256 citations

Asthma, Cxcr2 Antagonist, Allergy +7

A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers

Paul K. Paik, Ronglai Shen, Michael F. Berger et al. · Clinical Cancer Research · 2017 · 144 citations · Full text

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i> -Mutated Breast and Gynecologic Cancers

Udai Banerji, Emma Dean, José Alejandro Pérez Fidalgo et al. · Clinical Cancer Research · 2017 · 139 citations · Full text

The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD

A. Kirsten, Karin Förster, E. Radeczky et al. · Pulmonary Pharmacology & Therapeutics · 2015 · 86 citations

Advanced Lung Disease, Pulmonary Pharmacology, Pulmonary Medicine +6

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population

Nicholas C. Turner, Ashley E. Alarcon-Rozas, Anne Armstrong et al. · Annals of Oncology · 2019 · 83 citations · Full text